
Following the recent approval of Iovance's Amtagvi®, now is the perfect time to invest in TrAMPoline Pharma, Inc (TPI). TPI is a phase 1 clinical stage biotech company developing novel synthetic co-receptors to enhance all forms of cellular immunotherapy. Our lead product consists of a genetically modified, autologous tumor-infiltrating lymphocyte (TIL)-based cell therapy (MightyTILTM) to address the high unmet need in solid cancers. In addition to MightyTIL we are also developing a universal TCR-T immunotherapeutic for hematologic malignancies and solid tumors that could also be used for allogeneic applications.
Address
AuroraColorado
United States